Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data

Key Points

The study observes significant concordance between Ames and in vivo gene mutation assays for nitrosamines.
Key evidence reveals a robust dose-response relationship linked to carcinogenic effects.
Analysis using in vivo transgenic rodent models helps assess gene mutation related to NDSRIs more accurately.
This work highlights cross-assay relevance for assessing mutagenicity, suggesting further research on potency evaluation.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Observational analysis compares in vivo gene mutation potency in transgenic rodents for NDSRIs, indicating its relevance to carcinogenicity.

No takes yet. Share an insight, caveat, or question.

Jolly et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share